{"pmid":32259575,"title":"BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19.","text":["BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19.","Int J Antimicrob Agents","Praveen, D","Chowdary, Puvvada Ranadheer","Aanandhi, M Vijey","32259575"],"journal":"Int J Antimicrob Agents","authors":["Praveen, D","Chowdary, Puvvada Ranadheer","Aanandhi, M Vijey"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259575","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijantimicag.2020.105967","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663450393541083137,"score":7.9164424,"similar":[{"pmid":32278797,"title":"The use of Janus kinase inhibitors in the time of SARS-CoV-2.","text":["The use of Janus kinase inhibitors in the time of SARS-CoV-2.","J Am Acad Dermatol","Peterson, Danielle","Damsky, William","King, Brett","32278797"],"journal":"J Am Acad Dermatol","authors":["Peterson, Danielle","Damsky, William","King, Brett"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278797","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.03.099","keywords":["COVD-19","Janus kinase inhibitors","SARS-CoV-2","autoimmune disease","coronavirus","general dermatology","immunomodulators","immunosuppressants","medical dermatology"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663890922030497792,"score":78.69949},{"pmid":32268374,"title":"Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","text":["Keep Taking Your ACE Inhibitors and ARBs During the COVID 19 Pandemic.","J Travel Med","Speth, Robert C","32268374"],"journal":"J Travel Med","authors":["Speth, Robert C"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32268374","week":"202015|Apr 06 - Apr 12","doi":"10.1093/jtm/taaa045","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663609715757678593,"score":60.06179},{"pmid":32251638,"title":"Baricitinib for COVID-19: a suitable treatment?","text":["Baricitinib for COVID-19: a suitable treatment?","Lancet Infect Dis","Favalli, Ennio G","Biggioggero, Martina","Maioli, Gabriella","Caporali, Roberto","32251638"],"journal":"Lancet Infect Dis","authors":["Favalli, Ennio G","Biggioggero, Martina","Maioli, Gabriella","Caporali, Roberto"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251638","week":"202015|Apr 06 - Apr 12","doi":"10.1016/S1473-3099(20)30262-0","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352136205860865,"score":59.753876},{"pmid":32127666,"title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","text":["Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","Nat Rev Drug Discov","Li, Guangdi","De Clercq, Erik","32127666"],"journal":"Nat Rev Drug Discov","authors":["Li, Guangdi","De Clercq, Erik"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32127666","week":"202010|Mar 02 - Mar 08","doi":"10.1038/d41573-020-00016-0","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352134264946690,"score":57.697987},{"pmid":32119961,"pmcid":"PMC7089605","title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","text":["Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.","AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.","Life Sci","Elfiky, Abdo A","32119961"],"abstract":["AIMS: A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19). Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries. Human to human transmission is confirmed for COVID-19 by China a month ago. Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths. Additionally, MERS HCoV is responsible for 858 deaths out of about 2500 reported cases. The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp). MATERIALS AND METHODS: In this study, sequence analysis, modeling, and docking are used to build a model for Wuhan COVID-19 RdRp. Additionally, the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin. KEY FINDINGS: The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease. SIGNIFICANCE: The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs. Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection."],"journal":"Life Sci","authors":["Elfiky, Abdo A"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32119961","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.lfs.2020.117477","keywords":["COVID-19","Docking","Nucleotide inhibitors","RdRp","Sofosbuvir","Structural bioinformatics","Wuhan coronavirus"],"source":"PubMed","locations":["Sofosbuvir","Wuhan","China","Ribavirin"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Sofosbuvir","IDX184","Ribavirin"],"_version_":1663352134315278336,"score":52.70239}]}